Drug intelligence / Profile preview

OG-7191

Development stage: Preclinical
Lead developer: Organon
Modality: Small Molecules
Administration: Oral

Overview

OG-7191 is a preclinical small molecule inhibitor program targeting polycystic ovarian syndrome (PCOS), a common endocrine disorder in women associated with metabolic dysfunction, hyperandrogenism, and infertility. The mechanism of action is through inhibition of Aldo-keto-reductase family 1 member C3 (also known as 17β-HSD5), an enzyme involved in androgen biosynthesis. OG-7191 was originally developed by Forendo Pharma and is now in development by Organon, following acquisition of Forendo Pharma. There are currently no approved therapies for PCOS, making this a high-priority research area for its developer.

Targets

AKR1C3 (Aldo-keto reductase family 1 member C3)

Beyond the preview

Go deeper on OG-7191.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OG-7191.

Explore the full profile